Abstract
The neoplastic cells of mycosis fungoides (MF) and Sézary syndrome are recognized to be clonal expansions of “memory” T cells that home into the upper dermis and epidermis via the interplay of adhesion molecules and chemokines, and this may account for the marked effectiveness and even curative potential of various skin-directed therapies utilized to treat clinically early disease. However, because neoplastic T cells freely circulate and are detectable in extracutaneous tissues by PCR prior to other methods, effective long-term control of more advanced MF and Sézary syndrome, i.e. reduction of tumor burden and decreased risk of transformation into aggressive lymphoma, often requires long-term administration of a therapy with systemic activity in addition to skin-directed therapies. Therapies with immunomodulatory activities, e.g. interferon alfa, bexarotene or extracorporeal photochemotherapy (ECP), are probably superior to traditional cytotoxic drugs in this regard although the response rates are relatively low. Selected patients with advanced or biologically aggressive CTCL should be considered for an allogeneic stem cell transplantation regimen to induce a graft-versus-tumor response. New and emerging treatments include immunotoxins such as denileukin diftitox that selectively target neoplastic T cells, potent immunomodulatory cytokines such as rIL-12 to enhance innate antitumor immune mechanisms, novel immunotherapeutic approaches that use dendritic cells loaded with tumor-associated antigens or vaccination using synthetic peptides or DNA plasmids that express the variable region of the T cell receptor beta chain, and possibly gene and protein transduction therapy to correct intracellular defects in neoplastic T cells. Overall the future of therapy for CTCL seems quite optimistic.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baccard M, Marolleau JP, Rybojad M (1997) Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2. Arch Dermatol 133:656.
Berger CL, Longley J, Imaeda S, Christensen I, Heald P, Edelson RL (1998) Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 76:304–311.
Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T, Kuzel TM (2000) Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 25:111–113.
Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J (2000) Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 136:748–752.
de Coninck EC, Kim YH, Varghese A, Hoppe RT (2001) Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19:779–784.
Delfau-Larue M-H, Laroche L, Wechsler J, Lepage E, Lahet C, Asso-Bonnet M, Bagot M, Farcet J-P (2000) Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood 96:2987–2992.
Fox FE, Niu Z, Tobia A, Rook AH (1998) Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol 111:327–332.
Fraser-Andrews EA, Woolford AJ, Russell-Jones R, Seed PT, Whittaker SJ (2000) Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 114:117–121.
Gellrich S, Lukowsky A, Schilling T, Rutz S, Muche JM, Jahn S, Audring H, Sterry W (2000) Microanatomical compartments of clonal and reactive T cells in mycosis fungoides: molecular demonstration by single cell polymerase chain reaction of T cell receptor gene rearrangements. J Invest Dermatol 115:620–624.
Hoppe RT, Medeiros J, Warnke RA, Wood GS (1995) CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32:448–453.
Jones GW, Hoppe RT, Glatstein E (1995) Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1057–1076.
Kim YH, Hoppe RT (1999) Mycosis fungoides and the Sezary syndrome. Semin Oncol 26:276–289.
Link CJ, Seregina T, Traynor A, Burt RK (2000) Cellular suicide therapy of malignant disease. Stem Cells 18:220–226.
Muche J, Lukowsky A, Ahnhudt C, Gellrich S, Sterry W (2000) Peripheral blood T cell clonality in mycosis fungoides: an independent prognostic marker J Invest Dermatol 115:504–505.
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:367–388.
Resnik KS, Vonderheid EC (1993) Home ultraviolet phototherapy of early mycosis fungoides: long-term follow-up observations. J Am Acad Dermatol 29:73–77.
Rook AH, Heald P (1995) The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:997–1010.
Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DMF, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC (1999) Interleukin-12 therapy of cutaneous T- cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902–908.
Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatstein E, Ihde DC, Kaye F, Veach SR, Phelps R, O’Connor T, Trepel JB, Cotelingam JD, Gazdar AF, Minna JD, Bunn PA Jr (1988) Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 109:372–382.
Tensen CP, Vermeer MH, van der Stoop PM, van Beek P, Scheper RJ, Boorsma DM, Willemze R (1998) Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest Dermatol 111:222–226.
van Doom R, Van Haselen CW, van Voorst Vader PC, Geerts M-L, Heule F, de Rie M, Steijlen PM, Dekker SK, van Vloten WA, Willemze R (2000) Mycosis fungoides: disease evolution and prognosis in 309 Dutch patients. Arch Dermatol 136:504–510.
Vonderheid EC, Diamond LW, Lai SM, Au F, Dellavecchia M (1992) Lymph node histopathologic findings in cutaneous T-cell lymphoma. Am J Clin Pathol 97:121–129.
Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, Olsen E, Pittelkow M, Russell-Jones R, Takigawa M, Willemze R (2002) Update on erythrodermic cutaneous T cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95–106.
Wilson LD, Kacinski BM, Jones GW (1998) Local superficial radiotherapy in the management of minimal stage la cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 40:109–115.
Wolf P, Fink-Puches R, Cerroni L, Kerl H (1994) Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 31:678–680.
Zane C, Leali C, Airo P, De Panfilis G, Pinton PC (2001) “High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 44:629–633.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Vonderheid, E.C. (2002). Treatment of Cutaneous T Cell Lymphoma: 2001. In: Dummer, R., Nestle, F.O., Burg, G. (eds) Cancers of the Skin. Recent Results in Cancer Research, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59410-6_36
Download citation
DOI: https://doi.org/10.1007/978-3-642-59410-6_36
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63969-2
Online ISBN: 978-3-642-59410-6
eBook Packages: Springer Book Archive